Article Sidebar
Views pdf: 134
TREATMENT OUTCOMES OF STAGE IV LUNG ADENOCARCINOMA WITH A PEMETREXED-CONTAINING REGIMEN AT THANH HOA PROVINCIAL CANCER HOSPITAL
Main Article Content
Abstract
Objective: To evaluate the treatment response and progression-free survival (PFS) of the pemetrexed + platinum regimen in patients with stage IV lung adenocarcinoma at Thanh Hoa Oncology Hospital from July 2020 to December 2024. Patients and Methods: A combined retrospective and prospective longitudinal follow-up study was conducted on 56 patients with stage IV lung adenocarcinoma receiving the pemetrexed + platinum regimen. Results: The mean patient age was 63.2 ± 10.4 years, with a male-to-female ratio of 3.67:1. The objective response rate was 32.1%. The median progression-free survival (PFS) was 8.7 months. Subgroup analysis revealed significant differences in median PFS based on performance status and the number of metastatic organs (p<0.001 and p=0.002). The regimen was well tolerated. The main hematologic toxicity was anemia. Non-hematologic toxicities included elevated liver enzymes, fatigue, and nausea, all of which were grade I or II. Conclusion: The pemetrexed + platinum regimen is a promising treatment option with a response rate comparable to other regimens.
Article Details
Keywords
Lung adenocarcinoma, pemetrexed, pemetrexed platinum, treatment response, progression-free survival, PFS.
References
2. Travis WD, Brambilla E, Nicholson AG, et al (2015). The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 10(9):1243-1260. doi:10.1097/jto.0000000000000630
3. National Comprehensive Cancer Network (NCCN) (2021), Non-small cell lung cancer, NCCN Clinical Practice Guidelines in Oncology, Version 5.2021. https://www.nccn.org/ professionals/physician_gls/nscl.pdf
4. Joshi A, Noronha V, Patil VM, et al (2017). Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation? Chemotherapy research and practice. 2017:8196434. doi:10.1155/2017/8196434
5. Ito M, Horita N, Nagashima A, Kaneko T. (2019) Carboplatin plus pemetrexed for the elderly incurable chemo-naive nonsquamous non-small cell lung cancer: Meta-analysis. Asia-Pacific journal of clinical oncology. 15(2):e3-e10. doi:10.1111/ajco.12837
6. Nguyễn Thanh Ngọc, Nguyễn Thị Phương Thảo, Trần Hoàng Phương, Nguyễn Thị Quỳnh Lan, Lê Xuân Hà (2023). Kết quả điều trị bệnh nhân cao tuổi ung thư biểu mô tuyến của phổi giai đoạn IV bằng phác dồ pemetrexed-carboplatin. Tạp chí Y học Việt Nam. 530, 1B (tháng 9 2023). DOI:https://doi.org/10.51298/ vmj.v530i1B.6737.
7. Lê Thị Vân Anh, Nguyễn Thị Thái Hòa & Nguyễn Văn Hiếu (2022). Đánh giá kết quả điều trị pemetrexed bước 2 trong ung thư biểu mô tuyến của phổi giai đoạn IV. Tạp Chí Y học Việt Nam, 508(2). https://doi.org/10.51298/ vmj.v508i2.1628
8. Lê Viết Nam (2021). Đánh giá kết quả hóa trị phác đồ có Pemetrexedd trong ung thư phổi không tế bào nhỏ giai đoạn III-IV. Luận văn Bác sĩ Chuyên khoa II, Trường Đại học Y Hà Nội.